Enrolling

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

I4V-MC-JAHX -

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of juvenile idiopathic arthritis in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
1 year - 18 years
Conditions the trial is for
Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib
Could I receive a Placebo?
No
Enrollment Goal
190
Trial Dates
Apr 5, 2019 - Dec 2030
How long will I be in the trial?
The study will last about 264 weeks and may include up to 24 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have completed a previous study of baricitinib for the treatment of JIA

  • Participants must have not developed an allergy to baricitinib

Participants Must Not:

  • Participants must not have permanently stopped baricitinib in the prior study

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources